In the current trading session, CEL-SCI Corporation (CVM) stock surged by 20.45% to the price of $24.15 at the time of writing. CVM stock closed Wednesday’s session at $20.05 which is a gain. The stock volume traded today for 6.17 million shares. The shares exchanged hands five times the average volume of trade for the past 3 months. For the past year, CVM stock soared by 75.42%, and the past week it had also jumped 19.42%. In the past three and six months, the stock has gained 38.75%and 33.67% respectively. Furthermore, CEL-SCI is currently valued in the market at $766.11 million and has 40.53 million outstanding shares.
Biotech Investors are hinging on the success of Multikine phase 3
CEL-SCI stock rallied up to 45% this week. The boost is coming due to the gathering of results for the advancement in the phase III trial of its flagship investigational product Multikine.
On similar news related to Multikine, the company had seen a whopping gain of 82% in the month of January (on 26th) which was correlated with the WallStreetBets rally. Multikine is the only late-stage candidate of CVM stock and the reason behind the surge was the tweet by Geert Kersten – CEO of CEL-SCI which hyped up news about Multikine Phase III data’s release.
However, the news of the release of data had dragged on even passing the month of February, in which the Kerstentold the investors to keep their head high for the data and have confidence in the stock. Now the hype is aired around the full data analysis readout for the clinical study of immunotherapy. Success of this lead investigative product will lead to a life-changing course of action for patients with squamous cell carcinoma in the head or the neck.
Where will the success of Multikline lead the company?
The success of phase III Multikline will move the company to a phase where it can commercialize this treatment and boost the value of the CVM stock. Furthermore, the company will become an attractive buyout candidate for big pharma companies waiting to gain the benefits of its future potential.
CES-SCI’s lead product offering and operational background
CEL-SCI Corporation is a biotechnology company that specifically focuses on the design and development of novel treatments that are offered to target the demands and unmet needs of patients with certain diseases. The biotech company aims to develop immunotherapies for the treatment of infectious diseases as well as cancer. The leading investigational immunotherapy of CEL-SCI is Multikine. Multikine is being developed for the treatment of head and neck cancer. The immunotherapy is currently under clinical phase III trial.
CEL-SCI has also created a T-cell modulation procedure that can trigger the immune system to fight bacterial, parasitic and viral infections. The process is done by the system known as LEAPS which stands for Ligand Epitope Antigen Presentation System. LEAPS also focuses on the countering of autoimmune diseases, cancer, and allergies. The company uses this LEAPS system for a different platform which includes the treatment of rheumatoid arthritis and even a product candidate for coronavirus.
